Capricor Therapeutics Eyes 27.47% Upside and FDA Decision by August 22
Roth Capital set a $38 price target on Capricor Therapeutics, implying a 27.47% upside from its $29.81 stock price as its Duchenne therapy deramiocel nears the FDA’s August 22, 2026 PDUFA decision. Capricor holds $279 million cash to fund independent commercialization despite its NS Pharma legal dispute.
1. Price Target and Analyst Outlook
Roth Capital lowered Capricor Therapeutics’ price target to $38.00, reflecting a potential 27.47% upside from its trading level of $29.81. This adjustment underscores market expectations as the company approaches its pivotal FDA review.
2. Upcoming FDA Decision for Deramiocel
Capricor’s lead candidate, deramiocel, targeting Duchenne muscular dystrophy, faces a PDUFA target action date of August 22, 2026. Approval would mark a watershed moment for Capricor’s pipeline and open the door to its first commercial product.
3. Financial Resources and Commercialization Plans
The company maintains approximately $279.00 million in cash, sufficient to fund operations into Q4 2027 and support a standalone commercialization strategy. Capricor is expanding its manufacturing capacity and recruiting a Chief Commercial Officer in preparation for market launch.
4. Legal Dispute and Strategic Incentives
Capricor has filed suit to void its pricing agreement with NS Pharma, seeking full control over deramiocel’s distribution. A successful FDA approval could also yield a Priority Review Voucher, offering significant non-dilutive capital uplift.